285-IF; 25 ng/ml) for 24 hours, then stained with (A) Rabbit Anti-Human IL-15R alpha Monoclonal Antibody (Catalog # MAB10900) or (B) Rabbit IgG Control (
MAB1050), followed by APC-conjugated anti-Rabbit IgG secondary antibody (
F0111) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (
FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." class="big_lightbox">

285-IF; 25 ng/ml) for 24 hours, then stained with (A) Rabbit Anti-Human IL-15R alpha Monoclonal Antibody (Catalog # MAB10900) or (B) Rabbit IgG Control (
MAB1050), followed by APC-conjugated anti-Rabbit IgG secondary antibody (
F0111) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (
FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." alt="Human PBMC were treated with LPS (100 ng/ml) and recombinant human IFN gamma (
285-IF; 25 ng/ml) for 24 hours, then stained with (A) Rabbit Anti-Human IL-15R alpha Monoclonal Antibody (Catalog # MAB10900) or (B) Rabbit IgG Control (
MAB1050), followed by APC-conjugated anti-Rabbit IgG secondary antibody (
F0111) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (
FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." class="big_thumb" />
MAB1050), followed by APC-conjugated anti-Rabbit IgG secondary antibody (
F0111) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (
FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." class="big_lightbox">

MAB1050), followed by APC-conjugated anti-Rabbit IgG secondary antibody (
F0111) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (
FAB3832P). Staining was performed using our Staining Membrane-associated Proteins protocol." class="big_thumb" />